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Running head: Cardiovascular events with tamoxifen and letrozole 







Background: Compared to tamoxifen, adjuvant treatment with aromatase inhibitors improves 
disease outcomes of postmenopausal women with hormone receptor-positive early breast cancer. 
In the international, randomized, double-blind BIG 1-98 trial, 8,010 women were randomized to 
receive tamoxifen, letrozole, or sequential use of the agents for 5 years. With a focus on 
switching between agents, we investigated cardiovascular events over the entire 5-year treatment 
period.  
Methods: Of the 6,182 patients enrolled, 6,144 started trial treatment and were included in this 
analysis. Adverse events occurring during study treatment until 30 days after cessation were 
considered. Eight cardiovascular event types were defined. Cumulative incidence of events were 
estimated using the Kaplan-Meier method, without consideration for competing events. 
Multivariable Cox models estimated hazard ratios (HR) with 95% confidence intervals (CI) for 
pairwise comparisons of treatment arms. 
Results: While on study treatment, 6.5% of patients (n=397) had any cardiac events reported; for 
2.4%, the event was grade 3-5, of which 11 (0.2%) were grade 5. Letrozole monotherapy was 
associated with higher risk of grade 1-5 ischemic heart disease (HR=1.81; 95% CI, 1.06-3.08) 
compared with tamoxifen monotherapy. Patients assigned sequential tamoxifen−>letrozole 
(HR=1.59; 95% CI, 0.92-2.74) or sequential letrozole−>tamoxifen (HR=1.20; 95% CI, 0.68-
2.14) showed a lesser degree of risk elevation. Patients assigned to tamoxifen-containing 
regimens had significantly higher risk of grade 1-5 thromboembolic events (tamoxifen 
monotherapy HR=2.10; 95% CI, 1.42-3.12; tamoxifen→letrozole HR=1.96; 95% CI, 1.32-2.92; 





Conclusion: When initiating or switching between adjuvant endocrine treatments in 
postmenopausal patients, age and medical history, with special attention to prior cardiovascular 
events, should be balanced with expected benefit of the treatment. 







Aromatase inhibitors (AIs) improve disease outcomes, as compared with tamoxifen, among 
postmenopausal women with hormone receptor-positive early breast cancer and have become the 
standard of care.1 The four-arm, randomized, double-blind, phase III BIG 1-98 trial, which 
compared 5 years adjuvant letrozole versus tamoxifen versus their sequences, was one of the 
trials establishing the role of AIs in this population2-8. Letrozole improved disease-free survival, 
overall survival, distant recurrence-free interval, and breast cancer–free interval as compared 
with tamoxifen after median follow-up of 8.1 years6 and with longer follow up8. The safety 
profiles of the 4 treatment regimens differ substantially, in particular for the incidence of 
musculoskeletal events, gynecological and vasoactive symptoms, and cardiovascular events. 
Women assigned to sequential treatment with tamoxifen followed by letrozole 
(tamoxifen→letrozole) more frequently discontinued treatment (17.9% by 5 years) after 
switching because of adverse events when compared to the other 3 treatment arms. The 
letrozole-containing treatment arms had comparable rates of discontinuation up to 2 years (time 
of treatment switch in sequential arms), after which, the rates of discontinuation in the sequential 
arms increased9.  
 
The initial report of BIG 1-98 2 described an increased number of thromboembolic AEs in 
patients assigned tamoxifen and a small increase in some types and grades of cardiac AEs in 
patients assigned letrozole. A more detailed report, after a median follow-up of 30 months10, 
documented a low overall incidence of cardiovascular AEs, which differed between treatment 




events over the entire 5-year treatment period, with particular focus on the effects of switching 
between the two agents. 
 
Methods 
BIG 1-98 is an international, multicenter, randomized, double-blind, phase 3 trial that enrolled 
8,010 postmenopausal women with hormone receptor-positive operable invasive breast cancer6. 
Initially, between 1998 and 2000, 1,828 women were randomly assigned to receive monotherapy 
with letrozole (2.5 mg orally daily) or tamoxifen (20 mg orally daily) for 5 years. Beginning in 
1999 until 2003, 6,182 women were randomly assigned to one of four arms: monotherapy with 
tamoxifen or letrozole for 5 years or sequential therapy consisting of letrozole for two years 
followed by tamoxifen for three years, or tamoxifen for two years followed by letrozole for three 
years. In this study we focused on patients enrolled during the 4-arm randomization period. 
Patients who never started trial treatment were excluded.  
 
During trial drug administration, AEs were reported for each 6-month period using checkboxes 
on the case report forms while grading used the National Cancer Institute’s (NCI) Common 
Toxicity Criteria Version 2.0. The following targeted cardiovascular AEs were explicitly 
collected on the case report forms: myocardial infarction, cerebrovascular accident 
(CVA)/transient ischemic attack (TIA), angina requiring PTCA (percutaneous transluminal 
coronary angioplasty) or CABG (coronary artery bypass grafting), thromboembolic event, and 
hypercholesterolemia. Other AEs were collected using an open-text comment field for 
specification by the investigator. Open-text fields were reviewed and coded according to 




(IBCSG) Coordinating Center as part of the standard procedures of this double-blind trial. Three 
additional groups of events were identified: cardiac failure, other cardiovascular event, and 
hypertension. 
 
For the current study, AEs that occurred during the study treatment, or up to 30 days after 
patients discontinued treatment, were considered in order to define eight cardiovascular event 
types. We determined the worst grade of any cardiac event reported, which included reports of 
ischemic heart disease (including myocardial infarction, coronary artery disease, and angina), 
arrhythmia and cardiac arrest, cardiac failure, cardiopathy, valvular disease/large vessel disease, 
ECG changes (such as electrical conduction  blocks and bradycardia), sudden cardiac death, and 
cardiac NOS. The maximum grade of other cardiovascular events was determined from AE 
reports coded as cardiovascular NOS or other vascular. The highest grades of 
hypercholesterolemia, hypertension and CVA/TIA (only grade 3-5 were recorded) were each 
determined from a single coded AE type. We determined the highest grade of thromboembolic 
events, including reports of thromboembolism, deep vein thrombosis, phlebitis, and thrombosis.  
 
We further determined the time to first event of each cardiovascular event type, defined as time 
from randomization to the first report of the specific event type, or censored at 30 days after the 
last dose of study treatment. For CVA/TIA, time to first grade 3-5 event was examined. For other 
events, time to both first grade 1-5 and first grade 3-5 was examined. Patients randomized to 
receive five years of tamoxifen, but who chose to cross over to letrozole subsequent to the 





The baseline patient characteristics that were potential risk factors for developing cardiovascular 
events, including history of previous cardiovascular events, were summarized according to 
treatment groups. Cumulative incidence of events of interest was estimated using the Kaplan-
Meier method; no competing events were considered. Multivariate Cox proportional hazards 
models were used to estimate hazard ratios (HR) with 95% confidence intervals (CI) for pairwise 
comparisons of treatment arms and to test for differences between treatment groups using 3-
degree of freedom Wald test. The models were adjusted for age at randomization (>65 years vs. 
≤65 years), body mass index (normal vs. overweight vs. obese), history of any cardiac events, 
CVA/TIA events, hypercholesterolemia, hypertension, thromboembolic events, and other 
cardiovascular events. Ischemic heart disease and cardiac failure are subevents of any cardiac 
event, and therefore prior history of these events were not included individually in the 
multivariate models.  
 
Hazard rates for events of interest within a time interval were calculated using the maximum 
likelihood estimate from a piecewise exponential model. These estimates (reported per 100 
person-years) are number of events occurring within that time interval divided by the total 
patient-time at risk during that time interval. A constant hazard was estimated within each time 
interval, and tests comparing hazards between time intervals or between treatment arms were 
based on normal approximation of the difference between estimates. 
 








Of the 6,182 patients randomized during the 4-arm option, 6,144 patients started trial treatment 
and were included in this analysis. The median follow-up of the patients is 45.8 months. In the 
population, 30.0% of patients were over age 65, 34.2% were overweight and 20.4% obese, and 
17.6% were current smokers while 18.9% were former smokers (Table 1). History of 
hypertension was frequent, reported for 32.3% of patients, 13.3% had history of 
hypercholesterolemia, and 6.0% of patients had history of prior cardiac events. Prior 
thromboembolic events were reported for 3.3% and CVA/TIA for 1.3% of patients. Medical 
histories were well balanced across the four treatment arms (Figure 1). 
 
While on study treatment, 6.5% of patients had any cardiac events reported; for 2.4% of patients 
the event was grade 3-5, of which 11 (0.2%) were grade 5 (Table 2). Ischemic heart disease was 
reported for 2.0% of patients (1.2% grade 3-5) and cardiac failure for 1.0% of patients (0.5% 
grade 3-5). Results of the multivariate Cox models are shown in the Supplemental (S) tables 
online. No difference among treatment arms was observed in time to any grade 1-5 cardiac event 
(Figure 2a; adjusted overall p=0.33; Table S1), but differences emerged for time to any grade 3-
5 cardiac events (Figure 2b, adjusted overall p=0.05). After adjustment for baseline risk factors, 
letrozole monotherapy was associated with significantly higher risk of any grade 3-5 cardiac 
event (HR=1.83; 95% CI, 1.14-2.93) compared to tamoxifen monotherapy more so than 
sequential therapy (relative to tamoxifen monotherapy, tamoxifen→letrozole HR=1.18; 95% CI, 
0.71-1.96; letrozole→tamoxifen HR=1.24; 95% CI 0.75-2.06). Age older than 65, smoking 




prior CVA/TIA, any prior cardiac event, and hypertension (p=0.03, p<0.001, p=0.006, 
respectively) were associated with higher risk of any grade 3-5 cardiac event during treatment 
(Table S2).  
 
For the specific cardiac events differences among treatment groups were more apparent, 
including time to grade 1-5 ischemic heart disease (Figure 2c; adjusted overall p=0.12, Table 
S3) and grade 3-5 ischemic heart disease (Figure 2d; adjusted overall p=0.17, Table S4). After 
adjustment for baseline risk factors, including age older than 65, obesity, history of any prior 
cardiac events and hypertension (p<0.0001, p=0.03, p=0.02 and p=0.03, respectively; Table S3), 
letrozole monotherapy was associated with higher risk of grade 1-5 ischemic heart disease 
(HR=1.81; 95% CI, 1.06-3.08) compared with tamoxifen monotherapy. This association was 
observed to a lesser degree among patients on sequential tamoxifen→letrozole (HR=1.59; 95% 
CI, 0.92-2.74) but not for those on sequential letrozole→tamoxifen (HR=1.20; 95% CI, 0.68-
2.14). Similar results were observed for grade 3-5 ischemic heart disease (Table S4). 
 
For patients who received sequential tamoxifen→letrozole, the hazard of grade 1-5 ischemic 
heart disease was similar while receiving tamoxifen but remained high during subsequent 
letrozole treatment compared with patients who received tamoxifen monotherapy whose hazard 
was lower during the later years of tamoxifen monotherapy (hazards 0.047 tamoxifen→letrozole 
vs. 0.044 tamoxifen during the first two years of tamoxifen, p=0.84; 0.050 tamoxifen→letrozole 
vs. 0.020 tamoxifen during the subsequent three years, p=0.008; Figure 2c). Similarly for 
patients on sequential letrozole→tamoxifen, the hazard of ischemic heart disease declined and 




(hazards 0.042 letrozole→tamoxifen vs. 0.047 letrozole during the first two years of letrozole, 
p=0.75;  0.029 letrozole→tamoxifen vs 0.055 letrozole during subsequent three years, p=0.06).  
 
For cardiac failure, no statistically significant differences were observed among treatment groups 
for time to grade 1-5 cardiac failure (Figure 2e; relative to tamoxifen monotherapy, letrozole 
monotherapy HR=1.00; 95% CI 0.50-2.00; tamoxifen→letrozole HR=0.67; 95% CI 0.31-1.46; 
letrozole→tamoxifen HR=0.88; 95% CI 0.43-1.80, adjusted overall p=0.73), or for time to grade 
3-5 cardiac failure (Figure 2f; relative to tamoxifen monotherapy, letrozole monotherapy 
HR=1.04; 95% CI 0.42-2.57; tamoxifen→letrozole HR=0.52; 95% CI 0.17-1.57; 
letrozole→tamoxifen HR=0.74; 95% CI 0.27-1.99, adjusted overall p=0.58). 
 
The time to grade 1-5 hypercholesterolemia differed among groups (Figure 3a; relative to 
tamoxifen monotherapy, letrozole monotherapy HR=2.77; 95% CI 0.2.45-3.14; 
tamoxifen→letrozole HR=1.74; 95% CI 1.53-1.98; letrozole→tamoxifen HR=2.28; 95% CI 
2.00-2.59, adjusted overall p<0.0001), with incidence rates ranging from 24.5% on tamoxifen 
monotherapy to 53.2% on letrozole monotherapy. Grade 3-5 hypercholesterolemia only occurred 
in 23 patients (about 0.4%, Table 2). The reduced incidence of hypercholesterolemia under 
tamoxifen monotherapy was noted previously10. The pattern for grade 1-5 hypercholesterolemia 
on sequential therapy echoed that of ischemic heart disease. For patients on sequential 
tamoxifen→letrozole, the hazard of hypercholesterolemia was greater during letrozole treatment 
compared to tamoxifen monotherapy (hazards 0.76 tamoxifen→letrozole vs. 0.89 tamoxifen 
during the first two years of tamoxifen, p=0.07; 1.46 tamoxifen→letrozole vs. 0.35 tamoxifen 




hazard of hypercholesterolemia was lowest  during the final 3 years of tamoxifen compared to 
letrozole monotherapy (hazards 2.45 letrozole→tamoxifen vs. 2.55 letrozole during the first two 
years of letrozole, p=0.48; 0.26 letrozole→tamoxifen vs. 0.81 letrozole during the subsequent 
three years, p<0.001). No differences among treatment groups were observed for time to grade 3-
5 hypercholesterolemia (Figure 3b; relative to tamoxifen monotherapy, letrozole monotherapy 
HR=1.56; 95% CI 0.37-6.54; tamoxifen→letrozole HR=1.59; 95% CI 0.38-6.69; 
letrozole→tamoxifen HR=3.09; 95% CI 0.83-11.5, adjusted overall p=0.30). 
 
While on treatment, grade 1-5 hypertension was reported for 5.7% of patients (2.2% grade 3-5, 
Table 2). There were no differences among the treatment groups (Figure 3c, relative to 
tamoxifen monotherapy, letrozole monotherapy HR=0.96; 95% CI 0.71-1.31; 
tamoxifen→letrozole HR=1.18; 95% CI 0.87-1.58; letrozole→tamoxifen HR=0.96; 95% CI 
0.70-1.30, adjusted overall p=0.47), nor for grade 3-5 hypertension (Figure 3d, relative to 
tamoxifen monotherapy, letrozole monotherapy HR=0.95; 95% CI 0.54-1.65; 
tamoxifen→letrozole HR=1.54; 95% CI 0.93-2.54; letrozole→tamoxifen HR=1.41; 95% CI 
0.85-2.35, adjusted overall p=0.14). 
 
Other cardiovascular events were reported for 0.9% of patients (0.1% grade 3-5). No significant 
differences were observed among the treatment arms for time to other grade 1-5 cardiovascular 






While on study treatment, 4.1% of patients had any grade 1-5 thromboembolic events reported; 
for 2.4% of patients, the event was grade 3-5 (Table 2). The time to thromboembolic events 
differed among the groups both for time to grade 1-5 events (Figure 3e; adjusted overall 
p=0.001, Table S5) and for the subset of grade 3-5 events (Figure 3f, adjusted overall p=0.001, 
Table S6). After adjusting for baseline risk factors (including age over 65 years [p<0.001], 
overweight or obesity [p=0.01], history of prior thromboembolic event [p<0.001], cardiovascular 
event [p<0.001], and hypertension [p=0.005]), patients on tamoxifen-containing regimens had 
significantly higher risk of grade 1-5 thromboembolic events (tamoxifen monotherapy HR=2.10; 
95% CI 1.42-3.12; tamoxifen→letrozole HR=1.96; 95% CI 1.32-2.92; letrozole→tamoxifen 
HR=1.56; 95% CI 1.03-2.35; Table S5) as compared with patients on letrozole monotherapy. 
Similar results were observed for grade 3-5 thromboembolic events (Table S6). For patients on 
sequential letrozole→tamoxifen, the hazard of grade 1-5 thromboembolic events increased 
during the last 3 years on tamoxifen and was higher compared to patients who received letrozole 
monotherapy (hazards 0.048 letrozole→tamoxifen vs. 0.053 letrozole during the first two years 
of letrozole, p=0.77;  0.11 letrozole→tamoxifen vs. 0.05 letrozole  during the subsequent three 
years, p=0.002; Figure 3e). For patients on sequential tamoxifen→letrozole, the hazard of 
thromboembolic events declined during the last 3 years on letrozole and tended to be lower 
compared to patients who received tamoxifen monotherapy (hazards 0.17 tamoxifen→letrozole 
vs. 0.14 tamoxifen during the first two years of tamoxifen, p=0.27; 0.04 tamoxifen→letrozole vs. 
0.07 tamoxifen during the subsequent three years, p=0.07; Figure 3e). 
 
Grade 3-5 CVA/TIA was reported for 1.7% of patients while on treatment. No differences 




tamoxifen monotherapy, letrozole monotherapy HR=0.87; 95% CI 0.49-1.56; 
tamoxifen→letrozole HR=1.18; 95% CI 0.69-2.02; letrozole→tamoxifen HR=1.02; 95% CI 
0.58-1.78, adjusted overall p=0.76). 
 
Discussion 
In this analysis, we present detailed data about thromboembolic and cardiovascular events 
occurring during treatment with letrozole and/or tamoxifen in patients enrolled during the 4-arm 
randomization period of the randomized, double-blind BIG 1-98 trial. No differences were 
observed in the incidence rate of new or worsening hypertension or in the incidence rate of 
severe hypercholesterolemia (grade 3 and higher) as well as for CVA/TIA. Cholesterol-lowering 
medication was initiated more often among patients in the letrozole monotherapy arm compared 
to the tamoxifen and sequential arms11. These findings are in line with the known beneficial 
effect of tamoxifen on the lipid profile12, although the role of the different cardiometabolic 
effects of endocrine treatment is still not fully explained and further studies are needed13,14. As 
expected, patients treated with tamoxifen alone and tamoxifen followed by letrozole appeared to 
have a higher incidence of thromboembolic events during treatment with tamoxifen. For patients 
receiving two years of initial letrozole, the rate of thromboembolic events increased dramatically 
after they switched to tamoxifen. Patients at risk for such events, in particular those with a 
history of previous thromboembolic events, hypertension or other cardiovascular disease, should 
be cautious when considering the use of adjuvant treatment with tamoxifen. Patients on the 
letrozole monotherapy showed a higher incidence of grade 3-5 cardiac events and of grade 3-5 
ischemic heart disease, in particular those over 65 years of age. But, generally the incidence of 




was low with both drugs and comparable with data from other trials using an AI and 
tamoxifen1,15-18; however, these results are sometime inconsistent and the methods used to 
evaluate the safety are different. In particular the ATAC trial19 showed no significant difference 
in the occurrence of ischemic cardiovascular events, but the adverse events were not collected in 
a systematic predefined way.  In a recently published population-based cohort study20 aromatase 
inhibitors were associated with increased risks of heart failure and cardiovascular mortality 
compared with tamoxifen, this confirming the result of a systematic review and meta-analysis of 
randomized controlled trials and observational studies21. 
 
BIG1-98 showed a clinically meaningful improved DFS and in OS with IPCW analysis for the 
use of letrozole especially for patients at higher risk22,23. However, for postmenopausal patients 
taking adjuvant endocrine treatment, the initial choice of agents and also switching between 
endocrine agents, should be considered and balanced with the medical history, with special 
attention for cardiovascular events and the age of the patient, with the expected benefit of the 
treatment.  
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Table 1. Baseline patient characteristics and history of cardiovascular events prior to treatment, 
















N % N % N % N % N % 
Smoker 
20 1.3 23 1.5 21 1.4 27 1.8 91 1.5   Missing 
  Current  287 18.6 268 17.5 274 17.8 250 16.4 1079 17.6 
  Former 298 19.3 287 18.7 294 19.1 285 18.7 1164 18.9 
  Never 936 60.7 957 62.3 952 61.8 965 63.2 3810 62.0 
BMI 
54 3.5 61 4.0 44 2.9 44 2.9 203 3.3   Missing 
  Normal 646 41.9 642 41.8 649 42.1 645 42.2 2582 42.0 
  Overweight 522 33.9 528 34.4 535 34.7 519 34.0 2104 34.2 
  Obese 319 20.7 304 19.8 313 20.3 319 20.9 1255 20.4 





5 69.8 1055 69.1 4299 70.0   Age ≤65 
  Age > 65 462 30.0 445 29.0 466 30.2 472 30.9 1845 30.0 
History of Any Cardiac Events  100 6.5 88 5.7 88 5.7 90 5.9 366 6.0 



















N % N % N % N % N % 
History of Cardiac Failure1  5 0.3 1 0.1 2 0.1 6 0.4 14 0.2 
History of CVA/TIA Events  17 1.1 25 1.6 24 1.6 16 1.0 82 1.3 
History of Hypercholesterolemia  180 11.7 223 14.5 203 13.2 212 13.9 818 13.3 
History of Hypertension  493 32.0 483 31.5 525 34.1 484 31.7 1985 32.3 
History of Thromboembolic Events  48 3.1 51 3.3 49 3.2 55 3.6 203 3.3 
History of Other Cardiovascular Events  54 3.5 79 5.1 81 5.3 78 5.1 292 4.8 





Table 2. Incidence of cardiovascular events during 5 years of treatment, by randomized 














N % N % N % N % N % 
Any Cardiac Events           
  Grade 1-5 86 5.6 103 6.7 113 7.3 95 6.2 397 6.5 
  Grade 3-5 28 1.8 51 3.3 35 2.3 35 2.3 149 2.4 
  Grade 5 2 0.1 3 0.2 1 0.1 5 0.3 11 0.2 
Ischemic Heart Disease1           
  Grade 1-5 22 1.4 40 2.6 37 2.4 26 1.7 125 2.0 
  Grade 3-5 12 0.8 26 1.7 20 1.3 14 0.9 72 1.2 
Cardiac Failure1           
  Grade 1-5 17 1.1 16 1.0 12 0.8 15 1.0 60 1.0 
  Grade 3-5 9 0.6 10 0.7 5 0.3 8 0.5 32 0.5 
Other Cardiovascular Event           

















N % N % N % N % N % 
  Grade 3-5 1 0.1 2 0.1 0 0 3 0.2 6 0.1 
Hypercholesterolemia           
  Grade 1-5 377 24.5 816 53.2 637 41.3 679 44.5 2509 40.8 
  Grade 3-5 3 0.2 5 0.3 6 0.4 9 0.6 23 0.4 
Hypertension           
  Grade 1-5 86 5.6 86 5.6 96 6.2 81 5.3 349 5.7 
  Grade 3-5 28 1.8 27 1.8 40 2.6 39 2.6 134 2.2 
Thromboembolic Events           
  Grade 1-5 76 4.9 40 2.6 75 4.9 62 4.1 253 4.1 
  Grade 3-5 41 2.7 17 1.1 52 3.4 36 2.4 146 2.4 
CVA/TIA Events           
  Grade 3-5 24 1.6 22 1.4 30 1.9 26 1.7 102 1.7 
1 ischemic heart disease and cardiac failure are sub-events of any cardiac event
29 
 
Figure 1. Patient Inclusion Diagram. Abbreviations: ITT=intention-to-treat; Tam=tamoxifen; 

















Figure 2. Cumulative incidences plots of events of (a) time to any grade 1-5 cardiac events, 
(b) time to any grade 3-5 cardiac events, (c) time to any grade 1-5 ischemic heart disease, (d) 
time to any grade 3-5 ischemic heart disease, (e) time to any grade 1-5 cardiac failure and (f) 
time to any grade 3-5 cardiac failure. No competing events were considered. Abbreviations: 
Tam=tamoxifen; Let=letrozole; → indicates sequence of 2 years of one agent followed by 3 




















Figure 3. Cumulative incidences plots of events of (a) time to any grade 1-5 
hypercholesterolemia, (b) time to grade 3-5 hypercholesterolemia (c) time to any grade 1-5 
hypertension, (d) time to any grade 3-5 hypertension (e) time to any grade 1-5 
thromboembolic events, (f) time to any grade 3-5 thromboembolic events. No competing 
events were considered. Abbreviations: Tam=tamoxifen; Let=letrozole; → indicates 




























Figure 4. Cumulative incidence plot time to grade 3-5 CVA/TIA events. No competing 
events were considered. Abbreviations: Tam=tamoxifen; Let=letrozole; → indicates 
sequence of 2 years of one agent followed by 3 years of the other agent. 
 
 
